Publicacións (29) Publicacións de Eva Costa Arpín

2023

  1. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study

    Neurologia, Vol. 38, Núm. 6, pp. 379-386

2022

  1. Cognitive impairment in early multiple sclerosis

    MULTIPLE SCLEROSIS JOURNAL, Vol. 28, Núm. 3_SUPPL, pp. 904-905

  2. Real life efficacy and tolerability of cladribine: multicentre study in galicia (CLADRIGAL)

    MULTIPLE SCLEROSIS JOURNAL, Vol. 28, Núm. Supl. 3, pp. 893-894

2021

  1. Prevalence of cognitive impairment in a multiple sclerosis patients cohort with low disability

    MULTIPLE SCLEROSIS JOURNAL, Vol. 27, Núm. Supl 2, pp. 191

  2. Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

    Neurologia, Vol. 36, Núm. 5, pp. 346-352

  3. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 8, Núm. 5

  4. Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain

    Multiple Sclerosis and Related Disorders, Vol. 52

2020

  1. Efficacy and safety of fampridine for walking disability in multiple sclerosis

    Neurodegenerative Disease Management, Vol. 10, Núm. 5, pp. 277-287

  2. Epidemiology of multiple sclerosis in Santiago de Compostela (Spain)

    Acta Neurologica Scandinavica, Vol. 142, Núm. 3, pp. 267-274

2019

  1. Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test)

    Multiple Sclerosis and Related Disorders, Vol. 28, pp. 50-56

  2. Solitary sclerosis: management and therapeutic implications

    EUROPEAN JOURNAL OF NEUROLOGY, Vol. 26, Núm. Supl 1, pp. 928

2018

  1. A new electronic and brief neuropsychological scale to detect cognitive impairment (CI) in patients with multiple sclerosis (MS): Validation study of the MS-COG-e scale

    NEUROLOGY, Vol. 90, Núm. Sup.15, pp. P2.421

  2. Temporal trends on the incidence of multiple sclerosis in Santiago de Compostela (Spain)

    MULTIPLE SCLEROSIS JOURNAL, Vol. 24, Núm. Supl 2, pp. 764

2017

  1. Fampridine effects on upper limbs motor function and quality of life

    MULTIPLE SCLEROSIS JOURNAL, Vol. 23, Núm. Supl. 3, pp. 417

  2. Mental processment velocity in patients on treatment with fampridine

    MULTIPLE SCLEROSIS JOURNAL, Vol. 23, Núm. Supl. 3, pp. 417

  3. Real life efficacy and tolerability of teriflunomide: multicentre study in Galicia (TERIGAL)

    MULTIPLE SCLEROSIS JOURNAL, Vol. 23, Núm. Supl. 3, pp. 936

2016

  1. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab

    Neurodegenerative disease management, Vol. 6, Núm. 1, pp. 5-12

  2. Clinical response and tolerability of fampridine in clinical practice

    Neurodegenerative disease management, Vol. 6, Núm. 2, pp. 99-105

  3. Evolution and clinical implications of lymphopenia in patients with relapsing remitting multiple sclerosis on treatment with fingolimod

    MULTIPLE SCLEROSIS JOURNAL, Vol. 22, Núm. Supl. 3, pp. 805-806

  4. Fingolimod: Efectividad y seguridad en la práctica clínica habitual. Estudio observacional,retrospectivo y multicéntrico en Galicia

    Revista de Neurologia, Vol. 63, pp. S13-S18